Early quality of life benefits of icodextrin in XXXX .

@entity1 @entity8 @entity298 @entity1163 @entity2473 @entity1296 @entity413
Early quality of life benefits of icodextrin in @entity298 . BACKGROUND: The impact of new therapies on @entity1 quality of life (QOL) is emerging as an important indicator of the value of these therapies. In @entity1 on dialysis, previous QOL evaluations have focused mainly on comparative approaches between modalities, or on longitudinal trends within a modality, but few have evaluated technical innovations or introduction of new therapies. The aim of the present study was to assess the early effects of a new dialysis solution (icodextrin) on the QOL of @entity298 @entity1 . The QOL is compared with that of @entity1 on @entity413 , and the impact of demographic, and clinical characteristics on @entity1 ' QOL is examined. METHODS: The @entity8 quality of life questionnaire (KDQOL) was administered to @entity1 who participated in a phase III double-blind, parallel group, active-controlled trial to evaluate the efficacy and safety of a @entity298 ( @entity298 ) solution containing icodextrin in comparison with @entity413 @entity298 solution. A total of 93 @entity1 (58 icodextrin, and 35 @entity413 ) completed the questionnaire at both baseline and after 13 weeks. In addition to @entity1 QOL, @entity1 ' demographic and clinical characteristics were recorded at both baseline and 13 weeks. RESULTS: Mean change scores from baseline to 13 weeks of icodextrin @entity1 were substantially higher (> or =5) than @entity413 , particularly with respect to general health perception, physical functioning, role-physical, and many KDQOL symptom items such as lack of strength, washed out or drained, lack of appetite, @entity1163 or @entity1296 , dry skin, cramps after an exchange or treatment, cramps during an exchange or treatment, and @entity2473 or twitching. At 13 weeks, icodextrin @entity1 had significantly improved symptoms, and rated their health in general higher than those @entity1 in the @entity413 group. Upon multivariate analysis, icodextrin contributed significantly to the improvement of @entity1 ' mental health, general health, and symptoms such as @entity2473 or twitching, cramps during an exchange or treatment, cramps after an exchange or treatment, itchy skin, and @entity1163 or @entity1296 . CONCLUSIONS: Peritoneal dialysis @entity1 treated with icodextrin experienced substantial quality of life improvement at 13 weeks after the start of treatment when compared to @entity413 @entity1 . Further research is necessary to determine @entity1 ' quality of life over time in a longitudinal study setting.
